Today, AMP started a position in Cidara Therapeutics (CDTX) for its hypothetical fund. Cidara is a clinical-stage biotechnology company developing infectious disease-focused drugs. Its lead asset is CD-101 IV, a Phase 2 echinocandid anti fungal to treat systemic Candida infections, which is expected to read out in late 2017/early 2018.